| 141: RET/PTC1 in vitro models unveil a novel tumor suppressor miRNA in papillary thyroid carcinoma E Minna, P Romeo, L De Cecco, M Dugo, G Cassinelli, C Lanzi, S Pilotti, ... European Journal of Cancer, S31, 2014 | | 2014 |
| 141P Gene-expression pathways and dynamics during neoadjuvant chemo-free therapy predict pathologic complete response in ER+/HER2+ breast cancer (BC) M Dugo, B Gyorffy, G Bisagni, MA Colleoni, M Mansutti, C Zamagni, ... Annals of Oncology 32, S421, 2021 | | 2021 |
| 447: Classification of human cutaneous metastatic melanoma cell lines and clinical samples by receptor tyrosine kinases-and phenotype-driven gene expression signatures M Dugo, S Canevari, A Anichini, ML Sensi European Journal of Cancer, S108, 2014 | | 2014 |
| 59P Primary tumour and circulating tumour cell (CTC) copy number alterations (CNAs) in triple negative breast cancer (TNBC) patients (pts) treated with neoadjuvant chemotherapy … S Di Cosimo, M Silvestri, M Dugo, M Vismara, C Reduzzi, G Pruneri, ... Annals of Oncology 31, S35-S36, 2020 | | 2020 |
| 654MO A phase II prospective trial of frontline cabozantinib in metastatic collecting ducts renal cell carcinoma: the BONSAI trial (Meeturo 2) G Procopio, M Claps, P Sepe, S Buti, L De Cecco, A Devecchi, M Dugo, ... Annals of Oncology 32, S680, 2021 | 1 | 2021 |
| 812 comparison of microarray platforms for measuring differential MicroRNA expression in paired normal/cancer colon tissues M Callari, M Dugo, V Musella, E Marchesi, G Chiorino, MM Grand, ... european journal of cancer, S194, 2012 | 1 | 2012 |
| A Cross-Comparison of High-Throughput Platforms for Circulating MicroRNA Quantification, Agreement in Risk Classification, and Biomarker Discovery in Non-Small Cell Lung Cancer C Gargiuli, L De Cecco, A Mariancini, MF Iannò, A Micali, E Mancinelli, ... Frontiers in Oncology 12, 911613, 2022 | 2 | 2022 |
| A melanoma subtype with intrinsic resistance to BRAF inhibition identified by receptor tyrosine kinases gene-driven classification M Dugo, G Nicolini, G Tragni, I Bersani, A Tomassetti, V Colonna, ... Oncotarget 6 (7), 5118, 2015 | 51 | 2015 |
| A phase 2 prospective trial of cabozantinib as first-line treatment for metastatic collecting ducts renal cell carcinoma: The BONSAI trial (Meeturo 2) clinical trial … G Procopio, P Sepe, S Buti, M Claps, M Colecchia, L De Cecco, D Andrea, ... Journal of Clinical Oncology 39 (15_suppl), 4571-4571, 2021 | 9 | 2021 |
| A study on the combined interplay between stochastic fluctuations and the number of flagella in bacterial chemotaxis D Besozzi, P Cazzaniga, M Dugo, D Pescini, G Mauri arXiv preprint arXiv:0910.1415, 2009 | 8 | 2009 |
| A subset of genetic susceptibility variants for colorectal cancer also has prognostic value S Noci, M Dugo, F Bertola, F Melotti, A Vannelli, TA Dragani, A Galvan The Pharmacogenomics Journal 16 (2), 173-179, 2016 | 22 | 2016 |
| Abstract A039: Carnitine palmitoyltransferase IA: an emerging potential metabolic target to counteract HER2-targeted therapy resistance in HER2-positive breast cancer A Franceschini, LT Castagnoli, TI Triulzi, PA Corsetto, M Dugo, A Belfiore, ... Molecular Cancer Therapeutics 22 (12_Supplement), A039-A039, 2023 | | 2023 |
| Abstract A134: MiR-875-5p impairs prostate cancer metastasis by remodeling tumor secretome and enhances tumor radiation response via EGFR suppression N Fenderico, D Cominetti, R El Bezawy, M Tortoreto, M Dugo, R Valdagni, ... Molecular Cancer Therapeutics 14 (12_Supplement_2), A134-A134, 2015 | 1 | 2015 |
| Abstract A24: Bone marrow hematopoietic adaptation as a sensor of early, pre-invasive, epithelial malignancy C Chiodoni, AM Tomirotti, TA Renzi, M Dugo, V Cancila, C Tripodo, ... Cancer Research 78 (10_Supplement), A24-A24, 2018 | | 2018 |
| Abstract GS1-00: Single-cell spatial analysis by imaging mass cytometry and immunotherapy response in triple-negative breast cancer (TNBC) in the NeoTRIPaPDL1 trial G Bianchini, XQ Wang, E Danenberg, CS Huang, D Egle, M Callari, ... Cancer Research 82 (4_Supplement), GS1-00-GS1-00, 2022 | 12 | 2022 |
| Abstract P1-04-02: Immune milieu associated with PD-L1 status in TNBC is dependent on time of biomarker assessment and treatment received: A secondary analysis of the … M Callari, CS Huang, D Egle, B Bermejo, C Zamagni, M Dugo, M Thill, ... Cancer Research 82 (4_Supplement), P1-04-02-P1-04-02, 2022 | | 2022 |
| Abstract P2-02-19: Circulating tumor DNA detection anticipates disease recurrence in early stage breast cancer: A pilot study generating an observational confirmatory trial MG Daidone, S Di Cosimo, S Veneroni, F Cascone, L De Cecco, M Dugo, ... Cancer Research 78 (4_Supplement), P2-02-19-P2-02-19, 2018 | 1 | 2018 |
| Abstract P2-07-12: Triple negative breast cancer subtypes and early dynamics of the 27-gene IO score predict pCR in the NeoTRIPaPDL1 trial M Dugo, CS Huang, D Egle, B Bermejo, C Zamagni, RS Seitz, TJ Nielsen, ... Cancer Research 82 (4_Supplement), P2-07-12-P2-07-12, 2022 | 5 | 2022 |
| Abstract P3-07-08: Breast cancer in China reveals transcriptomic likeness to Caucasian breast cancer X Huang, M Dugo, M Callari, M Sandri, L DeCecco, ML Carcangiu, M Iorio, ... Cancer Research 73 (24_Supplement), P3-07-08-P3-07-08, 2013 | | 2013 |
| Abstract P5-02-26: The 27-gene IO score is associated with pathologic complete response (pCR) in HR+/HER2-breast cancer patients treated with pembrolizumab in the I-SPY2 Trial RS Seitz, TJ Nielsen, B Ring, CT Cronister, MG Varga, D Bailey, M Dugo, ... Cancer Research 83 (5_Supplement), P5-02-26-P5-02-26, 2023 | | 2023 |
